Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Complex Regional Pain Syndrome
Interventions: BRC-002, BRC-002 Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Healthy Volunteers
Interventions: Lecanemab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Neoplasms, Breast
Interventions: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more

Conditions: Locally Advanced Unresectable or Metastatic Melanoma
Interventions: Selinexor, Pembrolizumab; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Grayslake, Illinois • Austin, Texas

Conditions: Chronic Hepatitis C Infection
Interventions: Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more

Conditions: Healthy Participants
Interventions: LY4100511, Rabeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Conditions: Osteoarthritis, Knee
Interventions: KA34, Placebo; Drug
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 40 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Walnut Creek, California • Clearwater, Florida • Orlando, Florida + 1 more

Conditions: Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions: URG101, Placebo; Drug
Lead sponsor: Urigen; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Glendora, California • San Diego, California • Cartersville, Georgia + 1 more

Conditions: Healthy Volunteer
Interventions: GDC-0941, ketoconazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: PRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose; Drug
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 13
States / cities: Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more

Conditions: Healthy
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: mazindol; Drug
Lead sponsor: NLS Pharmaceutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more

Conditions: Breast Cancer, Metastatic Cancer
Interventions: adenovirus-mediated human interleukin-12; Biological
Lead sponsor: Max Sung; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ond-PR1, Ond-PR1 + MPh-IR, Ond-PR2, Ond-PR2 +_ MPh-IR; Drug
Lead sponsor: Tong Lee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Periodontitis, Periodontal Diseases
Interventions: Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline; Procedure · Drug
Lead sponsor: The Forsyth Institute; Other
Eligibility: 20 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Acute Myelogenous Leukemia (AML)
Interventions: Eltrombopag; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 60 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Atazanavir (current formulation), Atazanavir, powder for oral use 1 (POU1), Atazanavir (POU2); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 332
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Anxiety, Fear, Stress, Low Mood, Sleep
Interventions: The Daily Supplement; Dietary Supplement
Lead sponsor: Prima CBD; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Menopause
Interventions: ERr 731 - Micro-coated, ERr 731 - Enteric coated; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 35 Years to 64 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Gig Harbor, Washington

Search by objective public record fields.

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus

ERr 731® Formulation Evaluation